Mycoplasma Testing Market

Analysts at GMI Research estimates that the Mycoplasma Testing Market was worth USD 832 million in 2022, and forecast to touch USD 1,759 million in 2030, growing at a CAGR of 9.8% from 2023-2030.

Mycoplasma Testing Market Overview

Mycoplasma testing is bacterial class that is present in cell culture. These bacteria have the absence of cell walls which makes them resistant to antibiotics like penicillin. Mycoplasma can easily spread using droplets through cell culture. Mycoplasma contamination is complex thus, it requires testing. Mycoplasma testing consists of a group of tests to measure antibodies in the blood produced in response to a mycoplasma infection which detects the microbe directly through culturing the genetic material (DNA) in a body sample.

To have an edge over the competition by knowing the market dynamics and current trends of “Mycoplasma testing Market”, request for Sample Report here

Major Mycoplasma Testing Market Drivers

The factors driving the global Mycoplasma testing market include increasing prevelence of the infectious and chronic ailments such as Covid-19, cancer, HIV/AIDS among others, growing geriatric population and changing lifestyle. Increasing prevelence of the COVID-19 infections around the globe coupled with surge in demand for detecting the mycoplasma testing for detecting and diagnosing the number of infection cases and antibody response to the corona virus have impelled the market growth.

For instance, according to the Worldometer Information in April, globally an estimated around 140 million people are infected and the Covid-19 have caused 3 million deaths globally. It created massive demand for the diagnosis of the antibody antigen test to fight against Covid-19 infections around the globe. For contamination detection, various infections testing including mycoplasma testing is widely used in the co-infection testing of other pathogens such as mycoplasma pneumonia in patients with COVID-19.

Restraint in the Mycoplasma testing Market

However, high investment required which requires huge expenditure and the market is highly consolidated by the leading players which may hamper the mycoplasma testing market.

Do you want to know more about the Research process and detailed Methodology, Request Research Methodology of this report

Product- Segment Analysis

Based on product, the kits & reagents segment is expected to grow at the fastest rate in the global mycoplasma testing market during the study period. This is primarily attributed to rising demand for the extensive research & development in the biopharmaceutical & pharmaceutical industry. For instance, according to the Pharmaceutical Research and Manufacturers Association (PhRMA), the United States responsible for more than half the world’s R&D in pharmaceuticals equivalent to US$ 75 billion. Also, the biopharmaceutical industry accounted for more than US$ 1.3 trillion for United State’s economic output.

Technology – Segment Analysis

Based on the technology, ELISA holds the highest market share in 2019 in the global mycoplasma testing market owing to surge in the prevelence of the COVID-19 pandemic with surge in demand for the detection of symptoms of pneumonia with minimum time and high accuracy. Also, ELISA product is widely used in the pharmaceutical research activities for developing novel drugs.

Application – Segment Analysis

Based on the application, virus testing projected to have the largest market share over the forecast period in the global mycoplasma testing market in 2020, owing to rising launching of the new rapid testing kits with surge in the Covid-19 diagnosis. For instance, in 2020, Cipla launched rapid antigen test kits for detecting and diagnosis Covid-19. Similarly, Roche had launched new rapid corona virus test in Europe followed for regulatory clearance with point-of-care setting for both symptomatic and asymptomatic patients. This testing is widely accepted for the HIV infection diagnosis and many other infectious diseases testing.

In case, any of your pain points areas are not covered in the current scope of this report, Request for Free Customization here

Regional – Segment Analysis:

Based on the region, North America region is expected to dominate the global mycoplasma testing market in 2020 due to presence of leading players with growing pharmaceutical research and development activities with growing prevelence of the chronic and infectious diseases such as cancer, Covid-19 along with surge in investments by leading players. For instance, in 2019, Pfizer had invested US$ 500 million for expanding its a manufacturing facility in Sanford, North Carolina. Also, in 2020, The U.S. Department of Health and Human Services (HHS) had partnered with private leading players in the United States to expand U.S.-Based Pharmaceutical Manufacturing capacity for COVID-19 response.

Top Market Players

Various notable players operating in the market, include, Merck KGaA, THERMO FISHER SCIENTIFIC, INC, CHARLES RIVER LABORATORIES, Lonza Group Ltd., ROCHE DIAGNOSTICS, Bionique Testing Laboratories, Minerva Biolabs GmbH, SARTORIUS AG, InvivoGen, Agilent Technologies, Biotools B & M Labs, S.A., CREATIVE BIOARRAY, Boeing and among others. 

Key Developments:

• • In Feb, 2021, Merck has invested around US$ 21.66 million for strengthening its R&D and production site in Tempe, Arizona.
  • Also, in Feb 2021, Merck and BioNTech has made strategic partnership through accelerated supply and urgently needed lipids.
  • In March, 2021, Thermo Fisher has been collaborated with Protein Metrics for optimizing mass spectrometry data analysis for biopharmaceutical applications.

Segments covered in the Report:

The global mycoplasma testing market has been segmented on the basis of Product, Technology, solution, application, and key regions. Based on Product, the market is segmented into Kits & Reagents, (PCR Assay, Nucleic Acid Detection Kits (NAT), Elimination Kits, Standards & Controls, Stains and Others) Instruments, Services. In terms of technology, the global mycoplasma testing market is divided into PCR, ELISA, direct assay, indirect assay, enzymatic methods, microbial culture techniques and others. Based on application, the market is segmented into virus testing, cell line testing, end of production cells testing, and others. 

For detailed scope of the “Mycoplasma testing Market” report request a Sample Copy of the report

Report Coverage	Details
Market Revenues (2022)	USD 832 million
Market Base Year	2022
Market Forecast Period	2023-2030
Base Year & Forecast Units	Revenues (USD Million)
Market Segment	By Product, By Technology, By Application, By Region
Regional Coverage	Asia Pacific, Europe, North America, and RoW
Companies Profiled	Merck KGaA, THERMO FISHER SCIENTIFIC, INC, CHARLES RIVER LABORATORIES, Lonza Group Ltd., ROCHE DIAGNOSTICS, Bionique Testing Laboratories, Minerva Biolabs GmbH, SARTORIUS AG, InvivoGen, Agilent Technologies, Biotools B & M Labs, S.A. among others; a total of companies covered
25% Free Customization Available	We will customize this report up to 25% as a free customization to address our client’s specific requirements

Market Segmentation

Global Mycoplasma testing Market by Product

• • Kits & Reagents
    • PCR Assay
    • Nucleic Acid Detection Kits (NAT)
    • Elimination Kits
    • Standards & Controls
    • Stains
    • Others
  • Instruments
  • Services
  • Others

Global Mycoplasma testing Market by Technology

• • PCR
  • ELISA
  • Direct Assay
  • Indirect Assay
  • Enzymatic Methods
  • Microbial Culture Techniques
  • Others

Global Mycoplasma testing Market by Application

• • Virus Testing
  • Cell Line Testing
  • End of Production Cells Testing
  • Others

Global Mycoplasma testing Market by Region

• • North America Mycoplasma testing Market (Option 1: As a part of the free 25% customization)

    • By Product
    • By Technology
    • By Application
    • US Market All-Up
    • Canada Market All-Up

  • Europe Mycoplasma testing Market (Option 2: As a part of the free 25% customization)

    • By Product
    • By Technology
    • By Application
    • UK Market All-Up
    • Germany Market All-Up
    • France Market All-Up
    • Spain Market All-Up
    • Rest of Europe Market All-Up

  • Asia-Pacific Mycoplasma Testing Market (Option 3: As a part of the free 25% customization)

    • By Product
    • By Technology
    • By Application
    • China Market All-Up
    • India Market All-Up
    • Japan Market All-Up
    • Rest of APAC Market All-Up

  • RoW Mycoplasma Testing Market (Option 4: As a part of the free 25% customization)

    • By Product
    • By Technology
    • By Application
    • Brazil Market All-Up
    • South Africa Market All-Up
    • Saudi Arabia Market All-Up
    • UAE Market All-Up
    • Rest of world (remaining countries of the LAMEA region) Market All-Up

Major Players Operating in the Mycoplasma Testing (Option 5: As a part of the Free 25% Customization – Profiles of 5 Additional Companies of your Choice)

• • Merck KGaA
  • THERMO FISHER SCIENTIFIC, INC
  • CHARLES RIVER LABORATORIES
  • Lonza Group Ltd.
  • ROCHE DIAGNOSTICS
  • Bionique Testing Laboratories
  • Minerva Biolabs GmbH
  • SARTORIUS AG
  • InvivoGen
  • Agilent Technologies
  • Biotools B & M Labs, S.A.